We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Tests Evaluated for Filarial Antigenemia

By LabMedica International staff writers
Posted on 28 Sep 2017
Lymphatic filariasis (LF) is a major neglected tropical disease (NTD) that has been targeted for elimination by 2020. More...
The Global Programme to Eliminate Lymphatic Filariasis (GPELF, launched in 2000) uses repeated rounds of mass drug administration (MDA) with antifilarial drugs to interrupt transmission of the parasite.

Antigen testing is more sensitive for filarial infection than tests that detect microfilariae (Mf) in night blood. Point-of-care (POC) antigen tests can be performed with finger prick blood collected during the day or night, and they provide a visual result in 10 minutes. The performance of two POCs has been compared.

An international team of scientists working with those at Washington University School of Medicine (Saint Louis, MO, USA) compared the tests prior to MDA in two study sites (Congo and Côte d'Ivoire) and in three sites that had received MDA (Democratic Republic of Congo and two sites in Liberia). Data were analyzed with regard to positivity, agreement and heterogeneity. Models evaluated potential effects of age, gender, and blood microfilaria (Mf) counts in individuals and effects of endemicity and history of MDA at the village level.

The two POCs tested were the BinaxNOW Filariasis Immunochromatographic card test (ICT), and the more recently introduced Alere Filariasis Test Strip (FTS) both from Alere. All individuals with positive ICT and/or FTS tests were asked to provide a second blood sample between 10:00 PM and 1:00 AM for assessment of Wuchereria bancrofti Mf. In West Africa, fingerprick blood was collected in capillary tubes with EDTA anticoagulant, and this blood was used to prepare Mf smears.

The team analyzed the test results from a total of 3,682 individuals. FTS test scores in persons with positive test results were often higher than ICT scores (46.3% in pre-MDA sites and 35.2% in post-MDA sites). Only 14 subjects (0.4%) were ICT-positive and FTS-negative. Eleven of these cases were from Côte d'Ivoire (pre-MDA), and four of the 12 individuals with this profile who provided night blood were microfilaremic. Antigenemia rates were 8% and 22% higher by FTS than by ICT in pre-MDA and in post-MDA sites, respectively. FTS/ICT ratios were higher in areas with low infection rates.

The authors concluded that their study provided extensive new information on the performance of the FTS compared to ICT in Africa and it has confirmed the increased sensitivity of FTS reported in prior studies. Variability in FTS/ICT was related in part to endemicity level, history of MDA, and perhaps to the medications used for MDA. These results suggest that FTS should be superior to ICT for mapping, for transmission assessment surveys, and for post-MDA surveillance. The study was published on September 11, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Washington University School of Medicine


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR System
OnePCR
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: A family of molecules could help diagnose and treat breast cancer (Photo courtesy of Shutterstock)

Molecular Biomarkers Pave Way for New Tests to Diagnose and Predict Breast Cancer

Despite playing essential roles in tissue development and immune protection, the contribution of proteoglycans in cancer remains poorly understood. Some proteoglycans appear to shield the body from cancer,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.